Company profile

　　Wuhan Sanli Biotechnology Co., Ltd. is one of the largest animal serum manufacturers in China, with an annual production capacity of 120-150 tons of newborn bovine serum and a batch output of about 2.5 million ml. The products are sold to biological product manufacturers and research institutes nationwide. In 2013, we built a new standard plant off-site that meets the requirements of the new version of GMP (revised in 2010), with 2100 square metres of GMP production plant, 900 square metres of quality inspection building and 1100 square metres of storage area; we collect blood in the same way as doctors do surgery, and process serum in the same way as human plasma is processed in blood stations, controlling quality from the source. We are the first company in China to use the CIP online cleaning system to clean the tanks, pipelines and filtration equipment, and the serum is filled with advanced automatic filling machines, which is a reasonable layout and advanced equipment. The extremely low bacterial endotoxin and the rapid proliferation of cells are the characteristics of our products, and the excellent quality management system is the guarantee of our product quality.

　　In September 2016, the company passed the acceptance of "National Bovine Serum Production Enterprise Up to Standard" by China Pharmaceutical and Biotechnology Association, and in July 2016, the company passed ISO9001 international quality management system and international environmental management system certification.

　　We have won the trust of our customers and the recognition of the biologics industry for our honest services, and our company was awarded as "Contract-keeping and Credit-keeping" enterprise in Wuhan for eleven consecutive years from 2003 to 2013. "In 2009 and 2010, the company was awarded "Civilized and Honest Private Enterprise" by Wuhan Administration for Industry and Commerce for two consecutive years. "On March 8, 2004, the National Seminar on Animal Serum Production Management was held in Wuhan. The leaders of the National Institute for the Control of Pharmaceutical and Biological Products fully affirmed the contribution of our company to the Chinese biological products industry.

　　Scientific and technological innovation is the guideline of our company, and in October 2005, Sanli Biologicals established the "Sanli Serum Research Institute" in collaboration with China National Institute for the Control of Pharmaceutical and Biological Products (CNIBP) and Wuhan University School of Life Sciences, which established a good scientific and technological platform for the research and development of serum products. From November 2007 to the present, we have established a method for the simultaneous detection of viral contamination in bovine serum by real-time fluorescence quantitative PCR and immunofluorescence technology in collaboration with Wuhan University, which was supported by the National 863 Program. This is the first international use of real-time fluorescence quantitative PCR technology for quality control of serum, making a significant contribution to national biosecurity. The method has been established and six national patents have been applied for in 2009. Among them, the fluorescent antibody assay has been validated by the Chinese Institute for the Control of Pharmaceutical and Biological Products and written into the 2010 edition of the Chinese Pharmacopoeia.